Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 19/20 | 0.81 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.65 |
| ▸ | TTK | P33981 | 1/20 | 0.62 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.62 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24556862 | 0.93 | LRRK2 (0.77) | LRRK2SLCO1B1MAP3K9MKNK2 | |
| SCHEMBL29429993 | 0.90 | LRRK2 (1.00) | LRRK2TTKMAP3K9MKNK2 | |
| SCHEMBL18018784 | 0.90 | LRRK2 (1.00) | LRRK2TTKMAP3K9MKNK2 | |
| SCHEMBL21738312 | 0.89 | LRRK2 (0.78) | LRRK2TTKMAP3K9MKNK2 | |
| SCHEMBL18018906 | 0.88 | LRRK2 (1.00) | LRRK2SLCO1B1TTKMAP3K9MKNK2 | |
| SCHEMBL30718279 | 0.88 | LRRK2 (0.75) | LRRK2SLCO1B1TTKMAP3K9MKNK2 | |
| SCHEMBL18018902 | 0.86 | LRRK2 (1.00) | LRRK2SLCO1B1TTKMAP3K9MKNK2 | |
| SCHEMBL21738325 | 0.86 | LRRK2 (0.73) | LRRK2TTKMAP3K9MKNK2 | |
| SCHEMBL7459229 | 0.84 | LRRK2 (1.00) | LRRK2MAP3K9MKNK2 | |
| SCHEMBL18018912 | 0.84 | LRRK2 (1.00) | LRRK2MAP3K9MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778604-B1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA FARBER CANCER INST INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20220204515-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2020232332-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20180244676-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3256475-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana-Farber Cancer Institute, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244676-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | LRRK2 1/4885SLCO1B1 3171/4885TTK 1181/4885 |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | LRRK2 1/4885SLCO1B1 3171/4885TTK 1181/4885 |
| US-20220204515-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, PARK7, PINK1 | LRRK2 1/4885SLCO1B1 4526/4885TTK 1820/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | LRRK2 1/4885SLCO1B1 3171/4885TTK 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.